George P Hemstreet 3rd
Overview
Explore the profile of George P Hemstreet 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
715
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carroll P, Parsons J, Andriole G, Bahnson R, Castle E, Catalona W, et al.
J Natl Compr Canc Netw
. 2016 May;
14(5):509-19.
PMID: 27160230
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer Early Detection provide recommendations for prostate cancer screening in healthy men who have elected to participate in an...
2.
Carroll P, Parsons J, Andriole G, Bahnson R, Barocas D, Castle E, et al.
J Natl Compr Canc Netw
. 2015 Dec;
13(12):1534-61.
PMID: 26656522
Prostate cancer represents a spectrum of disease that ranges from nonaggressive, slow-growing disease that may not require treatment to aggressive, fast-growing disease that does. The NCCN Guidelines for Prostate Cancer...
3.
Carroll P, Parsons J, Andriole G, Bahnson R, Barocas D, Catalona W, et al.
J Natl Compr Canc Netw
. 2014 Sep;
12(9):1211-9.
PMID: 25190691
The NCCN Guidelines for Prostate Cancer Early Detection provide recommendations for men choosing to participate in an early detection program for prostate cancer. These NCCN Guidelines Insights highlight notable recent...
4.
Hemstreet 3rd G, Rossi G, Pisarev V, Enke C, Helfner L, Hauke R, et al.
J Immunother
. 2012 Dec;
36(1):57-65.
PMID: 23211622
The immunogenicity of a cellular immunotherapy using genetically modified vaccines to express α(1,3)galactosyl epitopes (αGal) was evaluated in advanced prostate cancer (PC) patients. In this dose escalation phase I study,...
5.
Berglund R, Tangen C, Powell I, Lowe B, Haas G, Carroll P, et al.
Urology
. 2012 Mar;
79(3):633-7.
PMID: 22386416
Objective: To update the results with 10-year data of a phase II prospective trial of neoadjuvant hormonal therapy with goserelin acetate and flutamide followed by radical prostatectomy for locally advanced...
6.
Kaushik D, Teply B, Hemstreet 3rd G
Lasers Med Sci
. 2012 Feb;
27(5):1099-102.
PMID: 22370618
No abstract available.
7.
Wang J, Wang F, Hemstreet 3rd G
Prostate Cancer
. 2011 Nov;
2011:216169.
PMID: 22110982
Objective. The aim of this study was to examine the epidemiology, natural history, treatment pattern, and predictors of long-term survival of signet ring prostate carcinoma (SRPC) patients based on the...
8.
Villanueva C, Hemstreet 3rd G
Int Braz J Urol
. 2010 Dec;
36(6):710-5.
PMID: 21176277
Purpose: To determine the prevalence of different approaches to the difficult urethral catheterization (DUC) among urology residents (UR) in the United States (US). Materials And Methods: An email invitation to...
9.
Kawachi M, Bahnson R, Barry M, Busby J, Carroll P, Carter H, et al.
J Natl Compr Canc Netw
. 2010 Feb;
8(2):240-62.
PMID: 20141680
No abstract available.
10.
Huang D, Casale G, Tian J, Lele S, Pisarev V, Simpson M, et al.
Int J Cancer
. 2009 Aug;
126(2):315-27.
PMID: 19676054
Uridine diphosphate (UDP)-glucose dehydrogenase (UGDH) catalyzes the oxidation of UDP-glucose to yield UDP-glucuronic acid, a precursor for synthesis of glycosaminoglycans and proteoglycans that promote aggressive prostate cancer (PC) progression. The...